Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 13 | History Defined

Hims Stock Tumbles Down After Abrupt Exit of Novo Nordisk: Here's Everything That Went Wrong

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated Chinese manufacturers not approved or inspected by the FDA.

International Business Times UK

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug

Hims & Hers had partnered with the Danish pharmaceutical giant in April to sell Wegovy

The Independent UK

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

“I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next year.

Fortune

From AI to aerospace: Europe's most innovative companies shaping tomorrow

For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the standouts that are driving progress with success.

Fortune

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

MarketBeat

Breaking Down Thursday’s Top 3 Unusually Active Options

In Thursday’s unusual options activity, there were 1,399, split almost evenly between puts (705) and calls (694). Of the top 100 by Vol/OI ratios, the top three ratios range from 81.86 to 69.31.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Weight loss drugs linked to higher risk of eye damage in diabetic patients

Study finds medicines such as Ozempic associated with greater risk of developing age-related macular degeneration

The Guardian - UK

Tudor Pro, Uno-X and TotalEnergies scheduled to debut in Maryland Cycling Classic in September

Early commitments for women's race include Canyon-SRAM zondacrypto and EF Education-Oatly

Cycling News

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Barchart

The boomerang era: A slew of former CEOs are suiting up once more to take top roles at their old companies

From Novo Nordisk to UnitedHealth, onetime chief executives are returning to guide their former organizations in times of trouble.

Fortune

Analysts Think These Stocks Could More Than Double in Value

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

MarketBeat

Lawsuits are piling up as weight-loss drug users report losing their sight: ‘I definitely wouldn’t have taken it’

Edward Fanelli, 57, shared his regrets about taking Ozempic after he was diagnosed with a rare eye condition.

The Independent UK

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Stock Market Today: Investors Look on the Bright Side

A generally good week closes on another positive note, as investors, traders and speculators look for fresh catalysts.

Barchart

Is Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?

Novo Nordisk stock sinks as CEO Lars Fruergaard announces his resignation. Analysts are not happy with his departure but continue to see significant upside in NVO shares.

International Business Times

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Euronews

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Is It Time to Buy the Dip in Novo Nordisk Stock?

Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing

International Business Times

Europe's Biggest 'Green' Methanol Plant Opens In Denmark

Europe's largest "green" methanol plant opened in Denmark on Tuesday, boosting the continent's emissions reduction efforts -- with customers ranging from shipping giant Maersk to toymaker Lego and pharmaceutical firm Novo Nordisk.

The Guardian - UK

Drug price cuts: what is Trump planning and what will it mean for big pharma?

President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

The Independent UK

Health experts reveal weight-loss jabs can ‘prevent mealtime battles’ for children

Health experts presented findings showing the drugs helped severely obese youngsters shed pounds on top of the diet and lifestyle plan they were already following

Evening Standard

Weight-loss jabs for children ‘are effective and help prevent mealtime battles’

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.

Fortune

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.

The Guardian - UK

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

1 … 12 13 14 15

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.